These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25771695)

  • 1. Is the recent ban on animal testing of legal high products a fatal blow to the development of a legal market for 'low-risk' psychoactive products in New Zealand?
    Rychert M; Wilkins C
    Addiction; 2015 Apr; 110(4):714-5. PubMed ID: 25771695
    [No Abstract]   [Full Text] [Related]  

  • 2. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent developments with the New Zealand regulated market approach to 'low-risk' psychoactive products.
    Wilkins C; Rychert M
    Addiction; 2017 Jan; 112(1):34-36. PubMed ID: 27457711
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues with monitoring the safety of psychoactive products under a legal regulated market for new psychoactive substances ('legal highs') in New Zealand.
    Rychert M; Wilkins C; Witten K
    Drug Alcohol Rev; 2017 Sep; 36(5):589-596. PubMed ID: 28229493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What products are considered psychoactive under New Zealand's legal market for new psychoactive substances (NPS, 'legal highs')? Implications for law enforcement and penalties.
    Rychert M; Wilkins C
    Drug Test Anal; 2016 Aug; 8(8):768-78. PubMed ID: 26857892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The interim regulated legal market for NPS ('legal high') products in New Zealand: The impact of new retail restrictions and product licensing.
    Wilkins C
    Drug Test Anal; 2014; 6(7-8):868-75. PubMed ID: 24817124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent developments with the establishment of a regulated legal market for new psychoactive substances ('legal highs') in New Zealand.
    Wilkins C
    Drug Alcohol Rev; 2014 Nov; 33(6):678-80. PubMed ID: 25302553
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A critical analysis of the implementation of a legal regulated market for new psychoactive substances ("legal highs") in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2018 May; 55():88-94. PubMed ID: 29524738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal high industry business and lobbying strategies under a legal market for new psychoactive substances (NPS, 'legal highs') in New Zealand.
    Rychert M; Wilkins C
    Int J Drug Policy; 2016 Nov; 37():90-97. PubMed ID: 27639994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thirty-one psychoactive plants exempted from New Zealand's Psychoactive Substances Act 2013.
    Rychert M; Wilkins C
    Addiction; 2017 Jan; 112(1):181-182. PubMed ID: 27549982
    [No Abstract]   [Full Text] [Related]  

  • 13. The New Zealand Psychoactive Substances Act (PSA): a policy breakthrough or just a symbolic act?
    Bretteville-Jensen AL
    Addiction; 2014 Oct; 109(10):1590-1. PubMed ID: 25163706
    [No Abstract]   [Full Text] [Related]  

  • 14. Can new psychoactive substances be regulated effectively? An assessment of the British Psychoactive Substances Bill.
    Reuter P; Pardo B
    Addiction; 2017 Jan; 112(1):25-31. PubMed ID: 27220685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are government-approved products containing new psychoactive substances perceived to be safer and more socially acceptable than alcohol, tobacco and illegal drugs? Findings from a survey of police arrestees in New Zealand.
    Rychert M; Wilkins C; Parker K; Witten K
    Drug Alcohol Rev; 2018 Mar; 37(3):406-413. PubMed ID: 29285812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
    Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
    J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prohibition is a key driver of the new psychoactive substances (NPS) phenomenon.
    Rolles S; Kushlick D
    Addiction; 2014 Oct; 109(10):1589-90. PubMed ID: 25163705
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to commentaries.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1593-4. PubMed ID: 25163708
    [No Abstract]   [Full Text] [Related]  

  • 19. Regulating new psychoactive drugs: innovation leading to compromise.
    Schep LJ; Gee P; Tingle M; Galea S; Newcombe D
    BMJ; 2014 Aug; 349():g5085. PubMed ID: 25122194
    [No Abstract]   [Full Text] [Related]  

  • 20. The new psychoactive substances regime in New Zealand: a different approach to regulation.
    Wilkins C; Sheridan J; Adams P; Russell B; Ram S; Newcombe D
    J Psychopharmacol; 2013 Jul; 27(7):584-9. PubMed ID: 23739179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.